with FDA-approved products containing semaglutide, identified under the trade names Wegovy, Ozempic, and RYBELSUS, and should only be prescribed after a close consultation between a healthcare provider and a patient and should only be taken under the supervision of a healthcare provider," the company said in a statement
Individual variation in GLP-1 receptor sensitivity means that some people will be extremely sensitive to even small changes in drug concentration while others barely notice the difference between peak and trough
Mochi Health names its partner pharmacies in the portal and lets patients select one, which is rare in the compounded GLP-1 category
[1] [13] However, according to the Ozempic Summary of Product Characteristics (SmPC), this effect has not been shown to reduce the clinical efficacy of commonly tested medications significantly
Overall, the authors calculated that approximately 93 million patients would be eligible for treatment with semaglutide